POZEN, Inc. was founded in 1996 and is headquartered in Chapel Hill, North Carolina. POZEN, Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The company has development and commercialization alliances with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without aura in adults; and AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers.

Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).

Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

Abraxis BioScience, Inc. (Abraxis) is an integrated biotechnology company. The Company is engaged in the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients treatments for cancer and other critical illnesses. The Company’s portfolio includes protein-based nanoparticle chemotherapeutic compound (Abraxane), which is based on its tumor targeting technology known as the nab technology platform. Abraxis owns the worldwide rights to Abraxane, a next-generation, nanometer-sized, solvent-free taxane that was approved by the United States Food and Drug Administration (FDA) in January 2005 for its initial indication in the treatment of metastatic breast cancer and launched in February 2005. The Company’s product pipeline includes over five clinical oncology and cardiovascular product candidates in various stages of testing and development, including Abraxane and Coroxane for various indications.

Aptuit prefers to operate behind the scenes. A pharmaceutical services company, Aptuit offers a range of support services to biotech and other drug development companies, including early- to late-stage development of pharmaceutical ingredients, clinical studies support, information systems development, project management, and consulting services. The company operates from more than a dozen offices in North America, Europe, and the Asia-Pacific region and serves companies of all sizes. Aptuit was founded in 2004; private equity firm Welsh, Carson, Anderson & Stowe holds a significant ownership stake in the company.

China Sky One Medical, Inc. is engaged in the development, manufacture, marketing and sale of over-the-counter, branded nutritional supplements and over-the-counter plant and herb based pharmaceutical and medicinal products. Its principal products are external use Traditional Chinese Herbal Remedies/Medicines (TCM). The Company is also an integrated manufacturer, marketer and distributor of external use Chinese medicine products sold primarily in China and through Chinese domestic pharmaceutical chains. The Company sells both its own manufactured products, as well as medicinal and pharmaceutical products manufactured by others in China. All of its business is conducted through its wholly owned subsidiary, American California Pharmaceutical Group, Inc. (ACPG) which, in turn, wholly owns Harbin Tian Di Ren Medical Science and Technology Company (TDR). On April 3, 2008, TDR completed its acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.

Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company focuses on developing gene therapy treatments for oncology and neurotherapy. Its lead product,TroVax, is in testing for renal and colorectal cancer and is designed to stimulate the body's immune response to attack tumor cells. Another leading candidate, ProSavin, is in testing for treatment of Parkinson's disease. The company has several additional products in various stages of clinical development. Oxford BioMedica has awarded Sanofi-Aventis exclusive rights to develop and commercialize TroVax globally. The company's California-based BioMedica subsidiary handles its business development in North America and Asia.

Genzyme Diagnostics was founded in 1981. A division of Genzyme, it develops, manufactures, and distributes "in vitro" diagnostic products, including point-of-care tests. The division also produces the raw materials (such as enzymes and antibodies used in tests for diabetes, cholesterol, and pancreatitis) and chemical reagents used by other diagnostic test manufacturers to make their own diagnostic tests. The company's point-of-care products (tests administered at a patient's bedside) include tests for strep A, mononucleosis, and bacterial vaginitis; it also offers several different pregnancy tests.

Vical Incorporated was founded in 1987 and is based in San Diego, California. Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent development programs in the areas of infectious disease and cancer. These are a Phase III clinical trial using its Allovectin-7 immunotherapeutic in patients with metastatic melanoma; a Phase II clinical trial using its cytomegalovirus (CMV) DNA vaccine in hematopoietic cell transplant patients, and a Phase I clinical trial using its H5N1 pandemic influenza DNA vaccine formulated with its Vaxfectin adjuvant.

Clinical Data, Inc. company was founded in 1969 and is headquartered in Newton, Massachusetts. Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.